semaglutide + niacinamide alt titration Tirzepatide niacinamide: complete guide to the compounded combination 🎥 What is microdosing a

The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), a phase 3 study involving 17,604 adults with overweight or obesity and pre-existing CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48]

doi:10.1016/j.peptides.2011.03.014 Cheng J, Wu TJ, Butler B, Cheng K

Coaching ensures patients stay active, motivated, and accountable

How does this improve my health span